BIOTECH

A 2011 study notes the success rate in bringing new medicines to market in the past six years is only half of what it had been previously. Biotech drugs are twice more likely to gain approval than more traditional chemical drugs.

 

Moving from early stage Phase I clinical trials to FDA approval is roughly 10%, about half in earlier years.

 

Approval applications were filed for 55% of the drugs that made it to Phase III testing, and 80% of those gained eventual approval; though only half were approved on initial review.

SOURCE:  BIOMEDTRACKER 

In summary: 10% of biotechs move from early stage Phase I clinical trials to FDA approval, and only half of those are approved on initial review.